KPV 10mg research-guide - Peptide Society KPV Peptide Research Guide | KPV 10mg

Q: What does KPV stand for?

KPV represents lysine, proline and valine, the three amino acids that form the peptide.

Q: Is KPV the same as alpha-MSH?

No. Alpha-MSH is a 13-amino-acid peptide, while KPV consists only of its final three amino acids.

Q: What is KPV being researched for?

KPV has been examined in inflammatory-signaling, intestinal, epithelial, immune-cell and antimicrobial laboratory models. These research areas are not approved medical indications.

Q: Has KPV been proven to treat inflammatory bowel disease?

No. Findings from cell experiments and animal colitis models do not establish that KPV safely or effectively treats inflammatory bowel disease in humans.

Q: Is KPV approved for human use?

KPV is not established as an FDA-approved drug for diagnosing, treating, curing or preventing disease. This material is offered for laboratory research only.

What Is KPV?

KPV is an ultra-short tripeptide composed of the amino acids lysine, proline and valine. Its name comes directly from the standard one-letter abbreviations for those three amino acids: K, P and V.

The sequence corresponds to amino-acid residues 11–13 at the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a naturally occurring signaling peptide produced from the larger precursor protein proopiomelanocortin.

Laboratory investigators have studied KPV primarily because this short sequence appears to retain certain inflammation-modulating properties associated with alpha-MSH without reproducing all of the parent molecule’s biological activity.

Important distinction: Published KPV findings are largely based on cell-culture experiments, biochemical assays and animal models. These results do not establish that KPV is safe or effective for treating any condition in humans.

KPV Molecular Specifications

Common name	KPV
Peptide sequence	Lys–Pro–Val
One-letter sequence	KPV
Peptide length	Three amino acids
Biological origin	C-terminal amino-acid sequence of alpha-melanocyte-stimulating hormone
Research classification	Melanocortin-derived tripeptide and experimental inflammation-research compound
Primary research areas	Inflammatory signaling, intestinal models, epithelial biology, immune-cell signaling and antimicrobial activity
Regulatory status	Not established as an FDA-approved drug for diagnosing, treating, curing or preventing disease

Molecular details may differ when researchers use terminally modified forms, salts, conjugates or specialized delivery systems. Researchers should always consult the batch-specific certificate of analysis and technical documentation supplied with the material.

History and Scientific Origin

Interest in KPV developed from research into the broader melanocortin system and the immune-regulating properties of alpha-MSH. Researchers sought to identify the smallest portion of alpha-MSH capable of reproducing selected inflammation-related effects.

Experimental work identified the C-terminal sequence—residues 11 through 13—as an important bioactive region. This produced growing interest in KPV as a compact research model for examining how short peptide sequences may influence inflammatory and innate immune pathways.

Early studies examined KPV in inflammatory models and investigated whether its activity depended on melanocortin receptors. Later research expanded into intestinal transport, inflammatory bowel models, epithelial signaling, antimicrobial activity and targeted delivery systems.

How Is KPV Proposed to Work?

KPV does not yet have one universally established mechanism. Current research suggests that its observed effects may involve several interacting pathways that vary by cell type, tissue and experimental model.

PepT1 Transport

Cell and animal studies have investigated whether the peptide transporter PepT1 helps move KPV into intestinal epithelial and immune cells. PepT1 normally transports small dipeptides and tripeptides.

NF-kB Signaling

Laboratory experiments have reported reduced activation of NF-kB, a transcription pathway involved in controlling multiple inflammatory genes.

MAP-Kinase Pathways

Researchers have also examined KPV in relation to MAP-kinase signaling, which helps regulate cellular stress responses, inflammatory signaling and gene expression.

Cytokine Signaling

Experimental findings suggest possible effects on the production or activity of selected pro-inflammatory cytokines. The exact response depends on the model and study conditions.

Is KPV a conventional melanocortin-receptor agonist?

The answer remains uncertain. Some experiments indicate that KPV’s inflammation-related activity may occur partly or substantially independently of the melanocortin-1 receptor. This distinguishes KPV from longer melanocortin peptides and remains an active research question.

Proposed signaling mechanisms describe laboratory observations. They should not be interpreted as confirmed clinical mechanisms or evidence of therapeutic effectiveness.

KPV and Inflammatory-Signaling Research

A major focus of KPV research is its interaction with cellular pathways associated with inflammation. Experimental studies have evaluated KPV in models involving cytokine exposure, immune-cell activation and chemically induced inflammation.

Reported laboratory observations have included:

Changes in NF-kB activation in selected cell models.
Changes in MAP-kinase inflammatory signaling.
Reduced secretion or expression of selected cytokines.
Activity in experimental inflammation models that may not require a fully functional melanocortin-1 receptor.
Differences between KPV and the longer core sequences of alpha-MSH.

These findings have made KPV useful for investigating how very short peptides can influence complex immune-signaling networks. However, differences in experimental concentration, delivery method, tissue, species and disease model can substantially affect study results.

Intestinal and Colitis-Model Research

The intestinal research surrounding KPV is among its most extensively studied areas. Researchers have examined the tripeptide in cultured intestinal cells and in animal models of chemically induced colitis.

PepT1 and intestinal uptake

PepT1 is a transporter that recognizes small peptides. It is normally found predominantly in the small intestine, but research has reported increased colonic PepT1 expression under certain inflammatory conditions.

In experimental systems, KPV has been investigated as a PepT1 substrate. Researchers proposed that transport through PepT1 may help deliver KPV into epithelial and immune cells where it can interact with intracellular inflammatory pathways.

Animal models of intestinal inflammation

Mouse studies have examined KPV in dextran-sulfate-sodium and trinitrobenzene-sulfonic-acid colitis models. Some experiments reported changes in histologic inflammation, inflammatory-gene expression and disease-associated measurements.

Targeted delivery research

Because small peptides may be vulnerable to enzymatic degradation and rapid clearance, researchers have explored nanoparticles, polymers and other delivery systems designed to protect KPV and concentrate it in specific intestinal tissues.

Evidence limitation: Chemically induced colitis in animals does not perfectly reproduce Crohn’s disease, ulcerative colitis or other human gastrointestinal disorders. Preclinical findings cannot establish a human treatment outcome.

Skin and Epithelial Research

Alpha-MSH and related peptides are present in barrier tissues such as the skin and gastrointestinal tract. This has encouraged investigation into their possible roles in local immune defense and epithelial responses.

KPV has been studied in keratinocytes and other laboratory systems used to examine inflammatory signaling in skin-related cells. Investigators have evaluated whether KPV influences responses triggered by inflammatory mediators and whether its signaling differs from full-length alpha-MSH.

Research has also explored modified or immobilized melanocortin-derived sequences for use in biomaterials and topical-delivery concepts. Nevertheless, these applications remain experimental and should not be represented as proven dermatologic treatments.

Antimicrobial Research

Laboratory researchers have evaluated alpha-MSH and its C-terminal KPV sequence against selected microorganisms. Early in-vitro experiments reported antimicrobial activity involving organisms such as Staphylococcus aureus and Candida albicans.

This area is relevant to innate-immunity research because barrier tissues must simultaneously respond to microorganisms and regulate inflammation. Researchers continue to investigate whether short melanocortin-derived peptides could provide useful templates for designing future antimicrobial molecules.

In-vitro antimicrobial activity does not mean that a research peptide can safely or effectively treat an infection. KPV is not a substitute for an approved antibiotic, antifungal medication or professional medical evaluation.

Current Evidence and Research Limitations

KPV is an experimental compound. Although its published laboratory findings are scientifically interesting, several important limitations should be recognized.

A large portion of the evidence comes from cultured cells or animal models.
Animal inflammatory models do not fully duplicate human disease.
Different studies may use different peptide forms, concentrations, routes and delivery technologies.
Long-term human pharmacokinetics and safety have not been adequately established.
Standardized clinical dosing, contraindications and drug-interaction information have not been established.
Results from isolated cell pathways cannot predict a complete organism-level response.
Commercial research material should not be assumed equivalent to an approved pharmaceutical product.

Additional controlled research would be necessary to establish clinical safety, pharmacology, effectiveness and appropriate manufacturing standards for any proposed medical application.

Laboratory Handling and Storage

KPV should be handled only by trained personnel using an approved laboratory protocol. Storage requirements can vary depending on the peptide form, formulation, packaging and manufacturer.

Review the batch-specific certificate of analysis before use.
Follow the storage temperature stated on the product label or technical documentation.
Protect the material from unnecessary moisture and direct light.
Use sterile laboratory practices when required by the experimental protocol.
Avoid repeated temperature changes unless permitted by the applicable stability data.
Record lot number, preparation date and storage conditions in the laboratory record.
Dispose of laboratory materials according to institutional and local requirements.

This guide does not provide reconstitution, dosage, injection, administration or self-experimentation instructions.

KPV Frequently Asked Questions

What does KPV stand for?

KPV represents the one-letter amino-acid codes for lysine, proline and valine, the three amino acids that form the peptide.

Is KPV naturally occurring?

The KPV sequence occurs naturally as the C-terminal three-amino-acid segment of alpha-melanocyte-stimulating hormone. A laboratory KPV product is synthetically manufactured for research.

Is KPV the same as alpha-MSH?

No. Alpha-MSH is a longer 13-amino-acid peptide. KPV is only its final three-amino-acid sequence and does not reproduce every property of full-length alpha-MSH.

What is KPV being researched for?

Published research has examined KPV in inflammatory-signaling, intestinal, epithelial, immune-cell and antimicrobial laboratory models. These research categories are not approved medical indications.

Does KPV work through melanocortin receptors?

The mechanism remains under investigation. Some studies suggest that selected KPV effects may occur partly independently of the melanocortin-1 receptor.

What is PepT1?

PepT1 is a membrane transporter that moves certain dipeptides and tripeptides into cells. Researchers have studied whether PepT1 participates in KPV uptake in intestinal epithelial and immune-cell models.

Has KPV been proven to treat inflammatory bowel disease?

No. KPV has produced research findings in cultured cells and animal colitis models, but these findings do not prove that it safely or effectively treats inflammatory bowel disease in humans.

Is KPV an antibiotic?

No. Although in-vitro studies have examined antimicrobial activity, KPV is not an approved antibiotic and should not be used as a replacement for medical treatment.

Is KPV approved for human use?

KPV is not established as an FDA-approved drug for the diagnosis, treatment, cure or prevention of disease. Peptide Society supplies this material strictly for laboratory research purposes.

Does this page provide KPV dosage instructions?

No. This page is an educational research overview and does not provide dosing, administration, injection or self-use instructions.

Selected Scientific References

The following publications discuss KPV, alpha-MSH-derived peptides, intestinal transport, inflammatory signaling or antimicrobial laboratory research.

Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. View on PubMed
Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008. View on PubMed
Getting SJ, et al. Dissection of the anti-inflammatory effect of the core and C-terminal melanocortin peptides. Journal of Pharmacology and Experimental Therapeutics. 2003. View on PubMed
Cutuli M, et al. Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology. 2000. View on PubMed
Elliott RJ, et al. Alpha-melanocyte-stimulating hormone, MSH 11–13 KPV and adrenocorticotropic hormone signalling in human keratinocytes. Journal of Investigative Dermatology. 2004. View on PubMed
Luger TA, et al. Alpha-MSH-related peptides: a new class of anti-inflammatory and immunomodulating drugs. View full text